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ABSTRACT
Objectives: To conduct a pilot trial of a primary care
Symptoms Clinic for patients with medically
unexplained symptoms and evaluate recruitment and
retention, and acceptability of the intervention and to
estimate potential treatment effects for a full trial.
Trial design: Randomised parallel group pilot trial.
Setting: Primary care in one locality.
Participants: Primary care database and postal
questionnaire were used to identify patients with
multiple specialist referrals and multiple physical
symptoms unlikely to be explained by disease.
Interventions: General practitioner (GP) with
special interest ‘Symptoms Clinic’ + usual care
versus usual care alone. The Symptoms Clinic
comprised one long (1 h) and three short (20 min)
appointments.
Outcomes: Number of patients identiﬁed and
recruited; acceptability of the intervention (items from
Client Satisfaction Questionnaire and interview);
Medical Outcomes Survey Short Form 12 (SF-12)
physical component summary.
Randomisation: Automated blocked randomisation
accessed by telephone.
Blinding: None.
Numbers randomized: 16 to intervention and 16 to
usual care alone.
Recruitment: 72 patients, from seven GP practices,
had repeated specialist referrals and a Patient Health
Questionnaire (PHQ)-15 score of $10 indicating a high
probability of medically unexplained symptoms. 15
were ineligible and 25 declined to participate.
Numbers analysed: 26 patients; two patients
randomised to the intervention group were
incorrectly included, three patients in the intervention
group and one control did not complete outcome
measures.
Outcome: Most patients randomised to the Symptoms
Clinic found the intervention acceptable: eight out of 11
reported the intervention helped them to deal with their
problems. The mean difference between groups in
SF-12 physical component summary, adjusted for
baseline, was 3.8 points (SD 6).
Harms: No observed harms.
Conclusions: Patients with multiple medically
unexplained symptoms can be systematically identiﬁed
in primary care; a randomised trial comparing the
Symptoms Clinic with usual care is feasible and has
the potential to show clinically meaningful beneﬁt.
Trial registration: ISRCTN63083469.
INTRODUCTION
Physical symptoms that cannot be adequately
explained by organic pathology are common
in both primary and secondary care.
1 2 For
some patients (approximately 1% of the
population), the number, persistence or
intrusiveness of these so-called medically
unexplained symptoms (MUS) leads to
repeated consultation, referral for investiga-
tion and impaired quality of life.
34Patients
with MUS, who have been repeatedly
referred to specialists, have impaired physical
To cite: Burton C, Weller D,
Marsden W, et al. A primary
care Symptoms Clinic for
patients with medically
unexplained symptoms: pilot
randomised trial. BMJ Open
2012;2:e000513.
doi:10.1136/
bmjopen-2011-000513
< Prepublication history and
additional appendix for this
paper are available online. To
view these ﬁles please visit
the journal online (http://dx.
doi.org/10.1136/
bmjopen-2011-000513).
Received 13 November 2011
Accepted 6 January 2012
This ﬁnal article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
1Centre for Population Health
Sciences, University of
Edinburgh, Edinburgh, UK
2Psychological Medicine
Research, University of
Edinburgh, Royal Edinburgh
Hospital, Edinburgh, UK
Correspondence to
Dr Christopher Burton;
chris.burton@ed.ac.uk
ARTICLE SUMMARY
Article focus
- There are few effective non-specialist interven-
tions for patients with multiple medically unex-
plained symptoms in primary care.
- We developed a new general practitioner (GP)
with special interest ‘Symptoms Clinic’ and
carried out a pilot randomised trial.
- The pilot trial aimed to test the systematic
identiﬁcation of eligible patients, assess the
acceptability of the intervention and estimate
potential treatment effects for a larger trial.
Key messages
- Patients with multiple medically unexplained
symptoms can be identiﬁed systematically from
the primary care database and a symptom
questionnaire.
- The Symptoms Clinic appears to be an accept-
able model for patients.
- A larger trial using these methods is feasible.
Strengths and limitations of this study
- This study was carried out by one GP with
special interest in medically unexplained symp-
toms. Further work to demonstrate transferability
of the clinic model is needed before a larger trial.
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Open Access Researchand mental health and incur substantial health costs
with little apparent beneﬁt.
5
There is evidence for the efﬁcacy of intensive treat-
ment of severe MUS with cognitive behavioural therapy
delivered by specialists.
6 7 Specialist psychiatric consul-
tation followed by a management planning letter has
been found to offer only modest beneﬁt.
8 Trials of
teaching general practitioners (GPs) to use brief inter-
ventions such as reattribution in routine consultations
have failed to show consistent beneﬁt.
9e11 All these
approaches concentrate on making the link between
physical symptoms and underlying psychological cause.
An alternative approach is to initially provide conven-
tional biomedical explanations for MUS
12 13 and to only
embark on psychosocial talk when cued by the patient.
14
We have developed a primary care Symptoms Clinic
for patients with multiple MUS, which comprises
a structured set of consultations with a specially trained
GP with special interest. The GP explores acceptable
explanations for symptoms in terms of biological
(including neurological and cognitive) mechanisms
rather than psychological cause, provides empathic
support and then helps patients to address speciﬁc
symptom-maintaining factors by medication or with
cognitive behavioural techniques. Here, we describe
a pilot randomised controlled trial, which compared this
Symptoms Clinic as a supplement to usual care with
usual primary care alone.
The aim of this study was to determine the feasibility of
conducting a larger trial of the Symptoms Clinic. We
examined the following components of feasibility:
systematic identiﬁcation of patients, trial recruitment
and retention, acceptability of the Symptoms Clinic
intervention and a preliminary estimation of potential
treatment effects.
METHODS
The study was conducted in Edinburgh between August
2009 and May 2010. Participating practices took part in
identifying potential patients, and the trial clinics were
held in an outpatient clinical treatment facility. The
study had approval from Lothian Research Ethics
Committee (reference 09/S1102/34) and was registered
(reference ISRCTN63083469).
Trial design
This was a pilot trial using an individually randomised
parallel group design with patients allocated equally to
intervention and control arms. The trial was conducted
with no major alterations to the initial protocol.
Participants
Eligible patients comprised adults aged 18e65 years and
registered with participating practices who met all the
three criteria: (1) they had been referred at least twice to
specialists in the preceding 3 years, (2) they currently
reported multiple physical symptoms and (3) their GP
believed that their symptoms were unlikely to be
adequately explained by physical disease. These criteria
were identiﬁed sequentially.
In the ﬁrst stage, practices carried out a computerised
search of medical records to identify patients aged
18e64 years who had been referred at least twice to
hospital outpatient clinics in the preceding 3 years, did
not have a diagnosis of serious illness (coronary heart
disease, stroke, cancer, severe mental illness) and had
one or more diagnostic codes potentially indicating
MUS. All diagnostic codes are listed in online appendix
1. As a pilot of this primary search strategy (search A) in
two additional practices returned fewer individuals than
expected due to low rates of coding for MUS, we added
a secondary search (search B) that required three or
more referrals but no codes for MUS. Searches were
developed speciﬁcally for this study (Campbell Software
Solutions) to run on the GPASS clinical system.
Current physical symptoms were assessed in patients
identiﬁed by the search for referrals by postal question-
naire. This included the Patient Health Questionnaire
(PHQ)-14, a modiﬁed version of the PHQ-15 scale
15 in
order to identify patients with multiple physical symp-
toms, which are commonly medically unexplained. We
omitted the item about menstrual symptoms because the
studypopulation included men and older women. Before
sending these, the practice GPs checked the list of names
to avoid sending the questionnaire to patients who were
seriouslyillor for whomitwould beclearlyinappropriate.
The postal PHQ-14 was accompanied by an information
sheet. We deﬁned multiple physical symptoms as a score
of $10 on the PHQ-14, indicating at least moderate
severity of MUS.
15 The likelihood that current symptoms
could not be explained by physical disease was assessed by
asking the GPs to review the casenotes of all patients who
returned the questionnaire with a PHQ-14 score of $10
and indicated an interest in taking part in the trial. The
GPs were also asked to exclude patients who were unable
to leave the house independently, or for whom other
health or social problems precluded an invitation to take
part in a study. Additional exclusion criteria were assessed
during the baseline assessment and were as follows:
patient reported thoughts of self harm more than a few
times in a week (an item in the PHQ-9), current self-
reported alcohol or drug problems and either current or
planned engagement in psychological treatment.
Baseline assessment and consent
The researcher (WM) carried out baseline assessment and
obtained informed consent during an interview. Baseline
measures included: age, sex and current occupation;
physical symptoms, assessed using the PHQ-14; health
status by Medical Outcomes Survey Short Form 12 (SF-12)
physical and mental component summaries; depression
by PHQ-9
16 and anxiety by General Anxiety Disorder 7
Questionnaire (GAD-7).
17
The general practice records (paper and electronic) of
all participants were reviewed by the researcher in order
to record patients’ prior use of both primary and
secondary healthcare services. This was done in order to
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Symptoms Clinic Pilot Trialprovide a baseline measure, but in view of the short
duration of this pilot trial, it was not repeated as a follow-
up measure. The number of consultations in the
precedingyearandreferralsinthepreceding3 yearswere
recorded, and the number of consultations and referrals
attributable to probable MUS were estimated using
a method based on the contents of the record entries.
18
Randomisation
Following completion of the baseline assessment,
patients were randomised to either usual care or inter-
vention (usual care + the Symptoms Clinic) by the
researcher. Randomisation was carried out by automated
telephone system using blocked allocation with variable
block size.
Usual care
Patients in both arms continued to receive usual care
from their registered general practice. This included
referral for investigation or treatment of symptoms as
the GP deemed appropriate.
Symptoms Clinic
Patients allocated to the Symptoms Clinic were offered
four appointments; the ﬁrst was of 1 h duration and the
subsequent three lasted 20 min. All consultations were at
the treatment centre, and patients were seen by the same
doctor (CB), an experienced GP with special interest in
MUS. The consultations were structured to ﬁrst hear the
patient’s experience of illness then to propose and
negotiate constructive explanations of physical symp-
toms. These explanations were used as the basis for
simple cognitive and behavioural actions to modify
symptoms and their impact. No speciﬁc attempt was
made to screen for common mental disorders; however,
patients were encouraged to describe their emotional
responses to symptoms and other events, and diagnostic
labels such as depression were discussed collaboratively
with the patient rather than imposed by the doctor.
Outcome measures
Outcome measures were chosen to measure four
components of feasibility: systematic identiﬁcation of
patients, trial recruitment and retention, acceptability
of the Symptoms Clinic intervention and estimation of
potential treatment effects.
The systematic identiﬁcation, recruitment and reten-
tion of trial participants was assessed by documenting
the numbers of patients at each stage of the study and by
checking that their baseline characteristics were similar
to those seen in our epidemiological study of patients
repeatedly referred with MUS.
4 5
The acceptability to participants of the Symptoms
Clinic patients was measured by administration of
a Client Satisfaction Questionnaire and by asking all
patients who had attended the clinic to participate in
a brief interview to determine their experiences of the
study procedures and the Symptoms Clinic. We noted
the number of eligible patients who declined to enter the
trial. We also followed-up patients who dropped out of
the trial in order to ascertain the reason for this. This
follow-up was carried out by telephone on two occasions
and then by letter from one of the investigators who had
no involvement with day-to-day contact of the trial. In
order to estimate likely treatment effects, we repeated the
following scales from baseline: PHQ-14, SF-12, PHQ-9
and GAD-7. In addition, patients completed the Patient
Global Impression of Change. These measures were
obtained by postal questionnaire (with telephone follow-
up of non-responders) 12 weeks after randomisation.
Sample size and statistical analysis
For this pilot trial, we aimed to randomise approximately
30 patients in order to obtain a reasonable range of
clinical conditions and test the clinic and trial proce-
dures adequately. The effects of the intervention were
estimated using analysis of covariance with baseline value
as a covariate.
RESULTS
All 15 practices in north-east Edinburgh were invited to
take part. The population of this urban area is socio-
economically diverse. Nine of the practices currently
used the GPASS clinical database on which the search
was run and six agreed to take part. We subsequently
recruited one additional practice. The total number of
patients registered with the seven practices was 45064.
Patient identiﬁcation and recruitment
The database searches identiﬁed 863 patients (1.9% of
the total general practice population), and question-
naires were sent to a randomly selected 486 of these. One
hundred and ﬁve patients (21.6%) responded and 72 of
thesehadaPHQ-14scoreof$10.GPsdeemed10ofthese
patients ineligible, and a further 22 were unable to attend
the baseline assessment. Five patients were excluded at
baselineassessmentbecauseofthoughtsofself-harm,and
a further three failed to attend, leaving 32 who were
randomised to either usual care or the Symptoms Clinic
plus usual care. These data are summarised in ﬁgure 1.
The number of patients identiﬁed by the search A was
smaller than anticipated, probably reﬂecting low rates of
coding for MUS syndromes within practices. However,
when we used the criterion of three or more referrals
without requiring any speciﬁc MUS syndrome (search
B), it identiﬁed three patients who on clinic assessment
had localised joint pain as their main symptom. While
these patients also reported other symptoms on the
PHQ-14, it was the localised joint pain, which had the
greatest effect on their functioning. As patients saw
addressing the joint pain (in one case surgically) as their
top priority, the Symptoms Clinic model was less appro-
priate than for patients who were still seeking an expla-
nation for their symptoms.
Patients’ characteristics
Baseline measures are shown in table 1. Patients had
substantially impaired physical and mental health status:
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standardised to population norms with mean and SD of
50 and 10, respectively, and these results placed the
participants in the lowest decile of the general popula-
tion, despite the absence of physical disease. Around half
the participating patients had comorbid anxiety or
depression. Participants were high users of health
services: they had a mean (SD) of 27 (11) GP consulta-
tions and 4.7 (1.8) specialist referrals over the preceding
3 years, of which 15 consultations and 3.4 referrals were
estimated from the records to be for MUS.
Trial retention and acceptability of clinic model and
procedures
All 16 patients randomised to the Symptoms Clinic
attended the ﬁrst appointment and 11 completed either
three or four appointments. Of the remainder, two were
clearly improving at the time they were seen and agreed
to early discharge; two found further attendance difﬁcult
after a second appointment and one declined any further
contact after the ﬁrst appointment. Several patients
randomised to usual care expressed some disappoint-
ment at the time of their allocation, although follow-up
response rates were comparable between the two groups.
Responses to the Client Satisfaction Questionnaire
from patients randomised to the Symptoms Clinic
suggested that the process was acceptable: eight out of
Figure 1 Flowchart for
Symptoms Clinic Pilot Trial.
Table 1 Baseline measures by allocation group
Usual
care
Symptoms
Clinic
N1 6 1 6
Men 4 7
Mean (SD) Mean (SD)
Age 45.9 (12.7) 49.2 (10.1)
PHQ-14 14.7 (2.6) 13.9 (3.3)
SF-12-PCS 35.6 (5.8) 35.0 (6.9)
SF-12-MCS 41.2 (10.4) 44.9 (11.2)
PHQ-9 8.0 (4.4) 9.9 (6.5)
GAD-7 5.5 (4.4) 6.9 (6.5)
N (%) N (%)
Patients with PHQ-9$10* 5 (31) 9 (56)
Patients with GAD-7$10y 3 (19) 5 (31)
*Indicates probable major depressive disorder.
yIndicates probable generalised anxiety disorder.
GAD-7, general anxiety disorder 7 questionnaire; MCS, mental
component summary; PCS, physical component summary; PHQ,
patient health questionnaire; SF-12, medical outcomes survey
short form 12.
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problems more effectively. Interviews suggested that
most patients appreciated the time and the explanatory
approach adopted by the Symptoms Clinic. A few
remained sceptical, indicating that they felt that the aim
was simply to assert that their problems were psycho-
logical, but most seemed comfortable with the balance
between psychological and physical components taken
by the clinic. There were few reported problems with the
trial procedures among participants.
Practices reported experiencing no major problems
with the process for identifying or recruiting patients.
The searches took <30 min; and the checking of the
resulting patient lists for those who were ineligible was
also quick and straightforward as patients were often well
known to the doctors.
Estimates of potential treatment effects
Outcome measures were obtained for 28 (84%) patients.
No follow-up data were available, despite repeated
requests from four patients, three in the intervention
group and one in usual care. Two of the non-responders
had predominantly musculoskeletal pain and would not
have been included in the search strategy, which
required one or more MUS syndrome diagnoses. Two
patients whose postal PHQ-14 had been above the entry
threshold of 10 but whose baseline PHQ-14 score was
below 10 were entered into the study in error and
randomised to the Symptoms Clinic. Because this ineli-
gibility was recorded before randomisation but not
recognised at the time, they were excluded from the
analysis.
Outcome measures are summarised by group in table 2.
For the SF-12 component scores, higher scores represent
better health; for PHQ-14, PHQ-9 and GAD-7, higher
scores represent worse health. The Patient Global
Impression of Change showed an improvement of one
or more levels in seven of 11 patients in the Symptoms
Clinic arm and two of 15 in the usual care arm. Table 2
includes no measures of statistical signiﬁcance, given the
small sample size, it does, however, include the SD of the
residuals from the ﬁtted analysis of covariance models.
Based on these, a difference in outcomes between
groups of two points in the PHQ-14 and three points in
the SF-12 Physical Component Score would represent
effect sizes of around 0.5 times the SD. Although we are
not aware of studies assessing clinically important
difference with these scales in a comparable population,
a standardised effect size of 0.5 is generally found to
represent a clinically meaningful difference.
19 We did
not measure subsequent healthcare use in this short-
term pilot study but regard this as an important outcome
for future studies.
DISCUSSION
Summary of main ﬁndings
This pilot trial supports the feasibility of conducting
a trial of the Symptoms Clinic. The trial procedures,
including identiﬁcation, recruitment and randomisation
were acceptable to patients. Nonetheless, a few patients
were lost to follow-up and further attention to the entry
criteria is warranted. The trial was not powered to detect
treatment effects, but the results were in keeping with
clinically meaningful beneﬁt.
Strengths and limitations
This study design had several strengths, particularly in
relation to identifying potential patients. Systematic
identiﬁcation of patients that combines high healthcare
use (referrals) with multiple symptoms on self-report
has not been used before but is in keeping with the
deﬁning features of patients with MUS.
20 The search
methods for this study were similar to our previous
epidemiological work
45using a database, however,
whereas previously we carried out detailed casenote
review to identify patients, in this study, we combined
repeated referrals with a high self-reported symptom
count. We found that the health-related quality of life
and prevalence of depression and anxiety in patients
recruited into this pilot study were similar to those in
our previous descriptive study of a similarly deﬁned
patient sample.
45This suggests that the sampling
method used in the trial achieved a representative
sample. In a future trial, other outcome measures could
be considered: in particular, a measure of healthcare
Table 2 Outcome measures at baseline and follow-up by intervention group
Measure
Usual care (N[15)
Symptoms Clinic
(N[11) Comparison*
Baseline Follow-up Baseline Follow-up Difference 95% CI SDy
PHQ-14 14.6 12.4 15 11.7 1.0z 3.8 to 1.9 3.5
SF-12-PCS 35.0 35.3 33.7 38.8 3.8 1.1 to 8.9 6.1
SF-12-MCS 41.2 45.2 45.8 44.5 2.3 7.6 to 3.1 6.4
PHQ-9 7.8 6.7 9.2 8.4 0.64 2.1 to 3.4 3.4
GAD-7 5.4 5.2 6.5 5.9 0.1 2.9 to 2.8 3.4
*By analysis of covariance including baseline value.
ySD of the residuals from the analysis of covariance.
zThe mean difference in scores between groups is inﬂuenced by one apparent outlier in the usual care arm with a drop of 12 points between
baseline and outcome. Removing this case changes the adjusted difference to 1.8 (4.3 to 0.7) with residual SD of 3.0.
GAD-7, general anxiety disorder 7 questionnaire; MCS, mental component summary; PCS, physical component summary; PHQ, patient health
questionnaire; SF-12, medical outcomes survey short form 12.
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this pilot study, which was designed to test procedures
rather than reach conclusions about effect.
21
Comparison with other recruitment and intervention
strategies
Previous studies of primary care interventions for
patients with MUS have depended on either question-
naire sampling,
9 GP identiﬁcation and referral
8 or
review of consultations by investigators to decide
whether symptoms were medically unexplained.
10 All
these have limitations for identifying patients with MUS
and high healthcare use. Only one trial has used
systematic searching of clinical records; this was
a lengthy process carried out by hand.
18 The recruitment
strategy we used had the advantage of combining activity
data from electronic records (referrals and diagnostic
coding) with symptoms reporting on questionnaire.
Although there have been policy statements advo-
cating intermediate care services for patients with
MUS,
22 there have been no formal studies of this
approach. The model here differs from conventional
approaches: it is much shorter than cognitive behav-
ioural therapy but longer and less psychologically
oriented than reattribution. Recent evidence suggests
that patients often actively resist reattribution.
23 Even
when they have anxiety and depression, patients with
MUS may see them as associated with rather than causal
to their physical symptoms.
24 Unlike the consultation
letter approach, the Symptom Clinic model aims to
negotiate a ‘medical’ explanation for symptoms
involving physiological processes, thus reducing uncer-
tainty and permitting an exit from the diagnostic cycle.
25
This explanation is then followed up over a series of
shorter consultations.
Implications for future research
This pilot study has identiﬁed an effective method for
systematically identifying patients in primary care who
have MUS and relatively high use of secondary care.
Further work is now needed to better understand
patients’ views, of which aspects of the intervention were
most helpful and to protocolise a ﬁnal version of the
intervention before undertaking deﬁnitive tests of its
efﬁcacy. Providing that the Symptoms Clinic model can
be shown to be delivered consistently by a range of
doctors, it offers a novel approach to a common problem
that warrants testing in a full-scale trial.
CONCLUSIONS
We found that the Symptoms Clinic intervention, and
the trial procedures we used to test its efﬁcacy, were
acceptable to patients. Given the prevalence of MUS and
their cost to health services, treatments are required that
can be effectively delivered in primary care, need limited
amounts of time per patient and can be taught relatively
quickly. The Symptoms Clinic meets these requirements
and now requires further evaluation.
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